Seraxis Eyes the Clinic Following $40 Million Capital Raise

Seraxis cell therapy replaces damaged or lost insulin-producing pancreatic cells
Published on :

Seraxis, which is currently located at the Pinkney Innovation Complex for Science & Technology at Montgomery College (PIC MC) in the County-owned Germantown Innovation Center is developing its lead therapy, SR-01, to eliminate the need for type 1 diabetes patients to inject insulin. SR-01 is a revolutionary therapy that could impact more than 4.5 million people in the world.

Gaithersburg’s Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ in Treatment of Diabetic Foot Osteomyelitis

Published on :

Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ in Treatment of Diabetic Foot Osteomyelitis GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to advancing therapies [….]

Seraxis Announces Closing of $40M Series C Financing Round

Published on :

GERMANTOWN, Md., Feb. 9, 2021 /PRNewswire/ –Seraxis, a biotech company developing a cell replacement therapy for insulin-dependent diabetes today announced the successful closing of a $40M Series C private financing round. The financing was [….]